SABS vs TWST

SAB Biotherapeutics, Inc. vs Twist Bioscience Corporation — Valuation Comparison 2026

SABS

Biological Products, (No Diagnostic Substances)
SAB Biotherapeutics, Inc.
Quality
5.0
out of 10
Value Trap
41
WARN
Price
$3.57
Last close
Models
12/13
Active
VS

TWST

Biological Products, (No Diagnostic Substances)
Twist Bioscience Corporation
Quality
4.5
out of 10
Value Trap
23
SAFE
Price
$69.03
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType SABS Fair ValueSABS Upside TWST Fair ValueTWST Upside
Bayesian DCF Intrinsic $1.27 -64.5% $16.85 -75.6%
Earnings Power Value Intrinsic $6.17 +77.9% $29.92 -50.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SABS vs TWST — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SABS vs TWST — Which Stock Is More Undervalued?

SABS scores higher with a 5.0/10 quality rating vs TWST's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SAB Biotherapeutics, Inc. (SABS) and Twist Bioscience Corporation (TWST) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SABS currently trades at $3.57 with a QOC of 5.0/10, while TWST trades at $69.03 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).